Laennec ampoule 2 ml of 50 pcs

Laennek – immunomodulating and hepatoprotective drug.

The drug exhibits immunomodulatory properties due to the ability to stimulate a humoral immunity and increases the functional activity of phagocytes and natural killer cells.

Increases the bactericidal activity of peripheral blood leukocytes, which is manifested in their ability to destroy the trapped pathogen. Cytokines that make up the drug, intensify metabolic and supervisory functions of skin cells.

Biologically active agents contained in the hydrolyzate stimulate regeneration (proliferation) hepatocytes exhibit detoxification properties, reduce deposition of lipid and cholesterol in hepatic cells, enhance the activity of tissue respiration, activate the metabolism in the liver reduce the intensity of the connective tissue in the liver.

Active substance:
Гидролизат плаценты человека

Manufacturer

Wound Clinic, Japan

Composition

1 vial contains:

Active substance:

Human placenta hydrolyzate 112 mg

Excipients:

water d / injection,

Sodium hydroxide or hydrochloric acid (for correction of pH).

Indications

• chronic recurrent herpes (in the complex therapy);
• atopic dermatitis secondary to severe, including complicated (in the complex therapy);
• chronic liver disease: steatohepatitis (alcoholic, metabolic and mixed etiology) – monotherapy

.

Contraindications

• children’s age;
• pregnancy;
• lactation;
• hypersensitivity to the drug.

Caution should be used in patients with polyvalent allergy to drugs in the elderly.

Side effects

Side effects have been reported in 3.7% of patients.

Clinically significant adverse reactions: Allergic reactions are possible.

Other undesirable phenomena: pain at the site of injection (2.56%), allergic reaction (redness, itching) (0.37%), numbness at the site of injection (0.37%), gynecomastia (0.37%) – a causal relationship with the administration of the drug has not been established .

How to accept, acceptance rate and dosage

With chronic relapsing herpes and atopic dermatitis drug is administered / drip in 10 ml (560 mg placenta hydrolyzate) drug (5 vials) were dissolved in 250-500 ml 5% dextrose solution or saline and administered via the cubital vein for 1.5-2 h. The injection is carried out 3 times a week at intervals of 2 days. The course of treatment of 10 injections.

In chronic liver diseases (steatohepatitis / alcoholic, metabolic or mixed aetiology /) introducing drug / m 2 mL / day (112 mg placenta hydrolyzate). Depending on severity of the disease injection frequency can be increased up to 2-3 times (6 ml) / day. The drug may be administered in / drip in 10 ml (560 mg placenta hydrolyzate) drug (5 vials) were dissolved in 250-500 ml 5% dextrose solution or saline and administered via the cubital vein for 1.5-2 hours injections performed 2 times. in Week. The course of treatment – 2-3 weeks.

Storage conditions

The drug should be protected from light, reach of children at a temperature of from 18 ° to 25 ° C.

Active substance

Гидролизат плаценты человека

Interaction

When mixing Laenneka solution with other drugs that are strong bases (pH greater than 8.5), the drug activity is reduced.

To date not revealed any other clinically significant drug interactions drug.

Special conditions

According to currently available data of the drug can be prescribed to the elderly. However, considering that the physiological functions of the elderly are deteriorating, the drug should be used under close supervision.

Use in Pediatrics

Safety trials of Laenneka in newborns (including premature) and minor children have not been conducted. Use in children is not recommended.

Overdose

Currently, the cases of drug overdose Laennek were reported.